Free Trial
NASDAQ:FBLG

FibroBiologics (FBLG) Stock Price, News & Analysis

FibroBiologics logo
$0.54 -0.06 (-10.41%)
Closing price 09/25/2025 04:00 PM Eastern
Extended Trading
$0.55 +0.01 (+2.28%)
As of 04:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About FibroBiologics Stock (NASDAQ:FBLG)

Advanced

Key Stats

Today's Range
$0.53
$0.60
50-Day Range
$0.53
$0.68
52-Week Range
$0.51
$3.89
Volume
698,343 shs
Average Volume
474,245 shs
Market Capitalization
$22.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.67
Consensus Rating
Buy

Company Overview

FibroBiologics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

FBLG MarketRank™: 

FibroBiologics scored higher than 61% of companies evaluated by MarketBeat, and ranked 510th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    FibroBiologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    FibroBiologics has a consensus price target of $12.67, representing about 2,247.0% upside from its current price of $0.54.

  • Amount of Analyst Coverage

    FibroBiologics has only been the subject of 2 research reports in the past 90 days.

  • Read more about FibroBiologics' stock forecast and price target.
  • Earnings Growth

    Earnings for FibroBiologics are expected to grow in the coming year, from ($0.53) to ($0.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of FibroBiologics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of FibroBiologics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    FibroBiologics has a P/B Ratio of 6.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about FibroBiologics' valuation and earnings.
  • Percentage of Shares Shorted

    3.06% of the float of FibroBiologics has been sold short.
  • Short Interest Ratio / Days to Cover

    FibroBiologics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in FibroBiologics has recently decreased by 16.58%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    FibroBiologics does not currently pay a dividend.

  • Dividend Growth

    FibroBiologics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.06% of the float of FibroBiologics has been sold short.
  • Short Interest Ratio / Days to Cover

    FibroBiologics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in FibroBiologics has recently decreased by 16.58%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    FibroBiologics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for FibroBiologics this week, compared to 2 articles on an average week.
  • Search Interest

    28 people have searched for FBLG on MarketBeat in the last 30 days. This is an increase of 56% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added FibroBiologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, FibroBiologics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.00% of the stock of FibroBiologics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about FibroBiologics' insider trading history.
Receive FBLG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FibroBiologics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FBLG Stock News Headlines

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa
FibroBiologics' (FBLG) "Buy" Rating Reiterated at HC Wainwright
Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
See More Headlines

FBLG Stock Analysis - Frequently Asked Questions

FibroBiologics' stock was trading at $2.00 at the start of the year. Since then, FBLG stock has decreased by 73.0% and is now trading at $0.5397.

FibroBiologics Inc. (NASDAQ:FBLG) announced its earnings results on Thursday, July, 31st. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.01.

FibroBiologics (FBLG) raised $144 million in an IPO on Wednesday, January 31st 2024. The company issued 4,806,226 shares at $30.00 per share.

Top institutional investors of FibroBiologics include Cascade Financial Partners LLC (0.69%), Geode Capital Management LLC (0.69%), Cerity Partners LLC (0.31%) and Jane Street Group LLC (0.23%).
View institutional ownership trends
.

Shares of FBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that FibroBiologics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Netflix (NFLX).

Company Calendar

Last Earnings
7/31/2025
Today
9/25/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FBLG
Previous Symbol
NASDAQ:FBLG
CIK
1958777
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

High Price Target
$16.00
Low Price Target
$10.00
Potential Upside/Downside
+2,247.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.16 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-710.25%
Return on Assets
-118.02%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.93
Quick Ratio
0.93

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.08 per share
Price / Book
6.75

Miscellaneous

Outstanding Shares
41,890,000
Free Float
33,511,000
Market Cap
$22.61 million
Optionable
N/A
Beta
-0.73
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:FBLG) was last updated on 9/26/2025 by MarketBeat.com Staff
From Our Partners